Table 3.
Imaging features of sclerosed hemangioma and sclerosing hemangiomas
| Hepatic sclerosed hemangioma (n = 12) |
Sclerosing cavernous hemangioma (n = 36) |
P value | |
|---|---|---|---|
| Location | 0.510‡ | ||
| Left lobe | 33.3% (4/12) | 47.2% (17/36) | |
| Right lobe | 66.7% (8/12) | 52.8% (19/36) | |
| Tumor size (cm) | 3.9 (1–36.5) | 7.5 (1–39) | 0.323† |
| Tumor shape | 0.316‡ | ||
| Round | 25% (3/12) | 44.4% (16/36) | |
| Irregular | 75% (9/12) | 55.6% (20/36) | |
| Capsular retraction | 8.3% (1/12) | 5.6% (2/36) | 1.000‡ |
| Slightly low density on plain CT | 88.9% (8/9) | 79.4% (27/34) | 1.000‡ |
| Calcification | 33.3% (3/9) | 8.8% (3/34) | 0.095‡ |
| Heterogeneous density | 55.6% (5/9) | 58.8% (20/34) | 1.000‡ |
| Slightly hypointense on T1-weighted image | 75% (6/8) | 80% (8/10) | 1.000‡ |
| T2-weighted image | 0.444‡ | ||
| Hyperintense (similar to cerebro-spinal fluid) | 12.5% (1/8) | 0 | |
| Slightly hyperintense | 87.5% (7/8) | 100% (10/10) | |
| Restriction on DWI | 0 | 0 | |
| Transient hepatic attenuation difference around the lesion | 0 | 16.7% (6/36) | 0.315‡ |
| Dynamic enhancement patterns | 0.000‡,* | ||
| Trend of centripetal enhancement accompanied by central non-enhancing areas | 25% (3/12) | 83.3% (30/36) | |
| Atypical | 75% (9/12) | 16.7% (6/36) |
*Significant level P < 0.05
†Mann–Whitney U test
‡Fisher exact test